|
|
Blood, 1 September 2004, Vol. 104, No. 5, pp. 1350-1355.
Prepublished online as a Blood First Edition Paper on May 18, 2004; DOI 10.1182/blood-2004-03-0896.
Previous Article | Next Article 
Submitted March 15, 2004
Accepted April 19, 2004
Anti-GPVI-associated ITP: An acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcR -chain complex from the human platelet surface
Brian Boylan, Hong Chen, Vipul Rathore, Cathy Paddock, Michael Salacz, Kenneth D Friedman, Brian R Curtis, Michelle Stapleton, Debra K Newman, Mark L Kahn, and Peter J Newman*
Blood Research Institute, The Blood Center of Southeastern Wisconsin, Milwaukee, WI, USA
Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
Blood Research Institute, The Blood Center of Southeastern Wisconsin, Milwaukee, WI, USA; Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
Blood Research Institute, The Blood Center of Southeastern Wisconsin, Milwaukee, WI, USA; Microbiology, Medical College of Wisconsin, Milwaukee, WI, USA
Pharmacology, Medical College of Wisconsin, Milwaukee, WI, USA; Cellular Biology, Medical College of Wisconsin, Milwaukee, WI, USA; Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI, USA
* Corresponding author; email: pjnewman{at}bcsew.edu.
Platelet glycoprotein (GP) VI is a 62 kDa membrane glycoprotein that exists on both human and murine platelets in a non-covalent complex with the Fc receptor (FcR) chain. The GPVI/FcR chain complex serves as the major activating receptor for collagen, as evidenced by observations that platelets genetically-deficient in GPVI or the FcR -chain are highly refractory to collagen-induced platelet activation. Recently, several different rat anti-murine GPVI monoclonal antibodies, termed JAQs 1, 2, and 3, were produced that had the unique property of immuno-depleting GPVI from the murine platelet surface and rendering them unresponsive to collagen or GPVI-specific agonists like convulxin or collagen-related peptide (CRP). Herein, we describe a patient with a mild bleeding disorder and a moderately-reduced platelet count whose platelets fail to become activated in response to collagen or CRP, and inefficiently adhere to and form thrombi on immobilized collagen under conditions of arterial shear. Though the amount of GPVI platelet mRNA and the nucleotide sequence of the GPVI gene were found to be normal, both GPVI and the FcR -chain were nearly absent from the platelet surface, and were markedly reduced in whole platelet detergent lysates. Patient plasma contained an autoantibody that bound specifically to GPVI-positive, normal platelets, and cleared soluble GPVI from her plasma, suggesting that that the patient suffers from a rare form of idiopathic thrombocytopenic purpura caused by a GPVI-specific autoantibody that mediates clearance of the GPVI/FcR -chain complex from the platelet surface. Since antibody-induced GPVI shedding has now been demonstrated in both humans and mice, these studies may provide a rationale for developing therapeutic reagents that induce temporary depletion of GPVI for the treatment of clinical thrombosis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Falet, M. P. Marchetti, K. M. Hoffmeister, M. J. Massaad, R. S. Geha, and J. H. Hartwig
Platelet-associated IgAs and impaired GPVI responses in platelets lacking WIP
Blood,
November 19, 2009;
114(21):
4729 - 4737.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Boylan, C. Gao, V. Rathore, J. C. Gill, D. K. Newman, and P. J. Newman
Identification of Fc{gamma}RIIa as the ITAM-bearing receptor mediating {alpha}IIb{beta}3 outside-in integrin signaling in human platelets
Blood,
October 1, 2008;
112(7):
2780 - 2786.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Varga-Szabo, I. Pleines, and B. Nieswandt
Cell Adhesion Mechanisms in Platelets
Arterioscler Thromb Vasc Biol,
March 1, 2008;
28(3):
403 - 412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Rao
Braking platelet activation: deactivating the receptors
Blood,
January 1, 2008;
111(1):
3 - 3.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Rabie, D. Varga-Szabo, M. Bender, R. Pozgaj, F. Lanza, T. Saito, S. P. Watson, and B. Nieswandt
Diverging signaling events control the pathway of GPVI down-regulation in vivo
Blood,
July 15, 2007;
110(2):
529 - 535.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. K. Andrews, D. Karunakaran, E. E. Gardiner, and M. C. Berndt
Platelet Receptor Proteolysis: A Mechanism for Downregulating Platelet Reactivity
Arterioscler Thromb Vasc Biol,
July 1, 2007;
27(7):
1511 - 1520.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Li, S. Lockyer, A. Concepcion, X. Gong, H. Takizawa, M. Guertin, Y. Matsumoto, J. Kambayashi, N. N. Tandon, and Y. Liu
The Fab Fragment of a Novel Anti-GPVI Monoclonal Antibody, OM4, Reduces In Vivo Thrombosis Without Bleeding Risk in Rats
Arterioscler Thromb Vasc Biol,
May 1, 2007;
27(5):
1199 - 1205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K Schallmoser, C Rosin, R Vormittag, M Brunner, D Dunkler, I Pabinger, and S Panzer
Specificities of Platelet Autoantibodies and Platelet Activation in Lupus Anticoagulant Patients: A Relation to their History of Thromboembolic Disease
Lupus,
August 1, 2006;
15(8):
507 - 514.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Boylan, M. C. Berndt, M. L. Kahn, and P. J. Newman
Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents
Blood,
August 1, 2006;
108(3):
908 - 914.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Schulte, H. P. Reusch, M. Pozgajova, D. Varga-Szabo, C. Gachet, and B. Nieswandt
Two-Phase Antithrombotic Protection After Anti-Glycoprotein VI Treatment in Mice
Arterioscler Thromb Vasc Biol,
July 1, 2006;
26(7):
1640 - 1647.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gruner, M. Prostredna, M. Koch, Y. Miura, V. Schulte, S. M. Jung, M. Moroi, and B. Nieswandt
Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice
Blood,
February 15, 2005;
105(4):
1492 - 1499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Stephens, Y. Yan, M. Jandrot-Perrus, J.-L. Villeval, K. J. Clemetson, and D. R. Phillips
Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen
Blood,
January 1, 2005;
105(1):
186 - 191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. E. Gardiner, J. F. Arthur, M. L. Kahn, M. C. Berndt, and R. K. Andrews
Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase
Blood,
December 1, 2004;
104(12):
3611 - 3617.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|